Biotech Company Advances Breakthrough Hyperinsulinism Treatment
Source: Streetwise Reports  (2/13/26)
Rezolute Inc. (RZLT:NASDAQ), a late-stage company focused on treating hypoglycemia caused by all forms of hyperinsulinism (HI), reports its financial results and provides a business update for the three months ending December 31, 2025. Read why one analyst considers the stock a Buy. More >

Technically Oversold with Support, Solid Patents, & A Heavyweight Board: Is This Stock Set to Soar?
Source: Stewart Thomson  (2/10/26)
Arch Biopartners Inc (ARCH:TSXV; ACHFF:OTCQB) is a therapeutic biotech company focused on developing novel, on-target drugs for acute kidney injury (AKI) and chronic kidney disease (CKD). The companys board and scientific advisory team of seasoned pros includes Dr. Patrick Vink (M.D., M.B.A.), Chairman of the Board, and Dr. Dan Muruve (M.D.), Chief Scientific Officer and internationally recognized nephrologist. The technical action on the charts suggests a significant surge in the stock price could be imminent. More >

CleanTech Company Advances FDA-Cleared Solution Toward Big Gains
Source: Streetwise Reports  (2/10/26)
Clean technology and life sciences company BioLargo Inc. (BLGO:OTCQX) announces that its subsidiary, Clyra Medical Technologies, Inc., has received its first commercial stocking order for ViaCLYR, its FDA-cleared wound irrigation solution. Read why one analyst believes the company has made significant progress in several initiatives. More >

Experts Spotlight a Persistent Barrier in Advanced Cancer Therapies
Source: Streetwise Reports  (2/9/26)
Rakovina Therapeutics Inc. (RKV:TSX.V) outlined its AI-driven approach to brain-penetrant ATR and mTOR inhibitors during the 9th Annual DNA Damage Response Inhibitors Summit in Boston. The company also reported inbound interest in its kt-3000 series as potential payloads for antibody-drug conjugates. More >

FDA Grants Orphan Drug Status to Experimental Melanoma Therapy After Phase 1 Results
Source: Streetwise Reports  (2/6/26)
TuHURA Biosciences Inc. (HURA:NASDAQ) said the FDA granted Orphan Drug Designation to IFx-2.0 for stage IIB to stage IV cutaneous melanoma. The designation was based on data from the companys previously completed Phase 1 clinical study. More >

Drug Developer Uncovers Excellent Progress in 200-Patient ALS Study
Source: Streetwise Reports  (2/2/26)
Biopharmaceutical company MediciNova Inc. (MNOV:NASDAQ) announces that by the end of January, 12 sites in the U.S. have been activated and 100 patients have been enrolled in its studying evaluating its treatment for ALS. Read what one analyst says investors should be looking for from the company in the coming year. More >

Biopharma Reaches 50% Enrollment in New ALS Drug Program
Source: Jason Kolbert  (2/2/26)
MediciNova Inc. (MNOV:NASDAQ) enrolls 100 patients in the SEANOBI Expanded Access Program for MN-166 (ibudilast), noted a D. Boral Capital report. Read on to learn the many potential catalysts ahead for this California-based firm. More >

Biopharmaceutical Co. Looking for Breakthrough in US$987.6M ALS Treatment Market
Source: Streetwise Reports  (1/30/26)
Biopharmaceutical firm MediciNova Inc. (MNOV:NASDAQ) reports that by the end of January, it has activated 12 sites in the U.S. and enrolled 100 patients in its study assessing its ALS treatment. Discover what one analyst suggests investors should watch for from the company in the upcoming year. More >

Clean Tech Developer Sees Massive Opportunity in PFAS Treatment
Source: Streetwise Reports  (1/29/26)
BioLargo Inc. (BLGO:OTCQX) announces that its patented Aqueous Electrostatic Concentrator (AEC) PFAS treatment system has been installed in New Jersey. Find out why the company sees massive upside for its products. More >

Environmental Firm Finds High-Value Position in PFAS Remediation Industry
Source: Streetwise Reports  (1/28/26)
BioLargo Inc. (BLGO:OTCQX) has announced the installation of its patented Aqueous Electrostatic Concentrator (AEC) PFAS treatment system in New Jersey. Discover why the company anticipates significant potential for its products. More >

Report of FDA Drug Approval Delay is 'Likely Noise': Analyst
Source: Douglas Tsao  (1/27/26)
Disc Medicine Inc.'s (IRON:NASDAQ) chances of bitopertin getting approved remain unaltered by the claims in a recent article, noted an H.C. Wainwright & Co. report. Read on to learn the reasons behind this opinion of the investment bank. More >

Biotech Co. Expands Testing Tied to its Cell Pouch Bio-hybrid Organ
Source: Dr. Douglas Loe  (1/13/26)
Sernova Biotherapeutics Inc. (SVA:TSX.V; SEOVF:OTC; PSH:XETRA) seeks to determine how a newly developed immunosuppressive agent and, separately, how a different type of islet will work in conjunction with cell implantation via its proven Cell Pouch Bio-hybrid Organ, noted a Leede Financial Inc. report. Read on to learn more about what this Speculative Buy-rated company is working on. More >

Analysts Highlight Notable H1/26 Catalysts in Biotech
Source: RBC Capital Markets  (1/12/26)
Despite the overall run-up in biotech names last year, the sector still offers "several attractive H1/26 catalyst set-ups, noted an RBC Capital Markets report. Find out which upcoming events the analysts like the most and the least. More >

AI Collaboration Expands to Accelerate Cancer Drug Discovery
Source: Streetwise Reports  (1/12/26)
Rakovina Therapeutics Inc. (RKV:TSX.V) has broadened its partnership with Variational AI to refine next-generation ATR inhibitors using generative AI. The agreement aims to streamline lead optimization for the company's kt-5000 series of small-molecule cancer drug candidates. More >

Expanded AI Collaboration Advances Optimization of Cancer Drug Candidates
Source: Streetwise Reports  (1/9/26)
Rakovina Therapeutics Inc. (RKV:TSX.V) has expanded its partnership with Variational AI to advance optimization of its kt-5000 ATR inhibitor series. Learn how the agreement deepens the company's use of generative AI to refine small-molecule drug candidates and accelerate preclinical selection. More >

Clean-Tech Co. Looks Forward to Massive Market Breakthroughs in 2026
Source: Streetwise Reports  (12/31/25)
BioLargo Inc.'s (BLGO:OTCQX) President and Chief Executive Officer Dennis P. Calvert notes the company is looking forward to its part in "what may be one of the largest infrastructure and technology investment cycles in history." More >

Clean-Tech Firm Anticipates Major Market Advancements in 2026
Source: Streetwise Reports  (12/30/25)
Dennis P. Calvert, President and CEO of BioLargo Inc. (BLGO:OTCQX), mentions that the company is eager to participate in "what may be one of the largest infrastructure and technology investment cycles in history." More >

Mineral Investor Chen Lin Argues Silver Moving From Bullion to Physical Asset, Reveals Picks
Source: Streetwise Reports  (12/16/25)
Seasoned minerals investor Chen Lin argues silver's 50-year breakout is not a routine cycle but a transition from bullion to a tightening "critical minerals" market. Read on to see what some of his top picks are, including one biotech company he thinks could be the next Eli Lilly. More >

Market Experts Uncover Excellent Buys During December 'Silly Season' Tax Selloff
Source: Streetwise Reports  (12/15/25)
Every December, tax-loss selling tends to exert downward pressure on certain stocks as investors aim to offset capital gains. Streetwise Reports asked some of its frequent contributors to add their own thoughts on the other "holiday season" and give their own picks for good bargains. More >

Tech Firm Partners to Advance AI-Powered Support for MDs
Source: Streetwise Reports  (12/11/25)
Rocket Doctor AI Inc.'s (AIDR:CSE; TREIF:OTC; 939:FRA) Clinical Decision Support System is being deployed in Alberta, Canada, on a small scale for a trial period with the goal of expanding it province-wide next year. This company's stock is rated Speculative Buy; read on to learn why. More >

Clean Tech Co.'s 'Forever Chemicals' Solution Featured in Industry Magazine
Source: Streetwise Reports  (12/8/25)
BioLargo Inc. (BLGO:OTCQX) subsidiary BioLargo Equipment Solutions & Technologies Inc. (BEST) is prominently featured in Chemical Engineering magazine for its advancements in electrostatic PFAS treatment technology. Find out why one expert likes this stock long-term. More >

AI-Powered Healthcare Co. Gains Traction as US Expansion Accelerates
Source: John Newell  (12/8/25)
John Newell of John Newell & Associates shares why he thinks Rocket Doctor AI (AIDR:CSE; TREIF:OTC; 939:FRA) is a Speculative Buy. More >

Data on 2 Drugs, Identified Via AI, Shared at Conference
Source: Dr. Douglas Loe  (12/4/25)
Rakovina Therapeutics Inc.'s (RKV:TSX.V) preclinical ATR inhibitors, Compound A and Compound C, exhibit similarities to two clinical-stage drugs in the same class, noted a Leede Financial Inc. report. More >

AI Breakthroughs Drive New Momentum in Oncology Research
Source: Streetwise Reports  (12/3/25)
Rakovina Therapeutics Inc. (RKV:TSX.V) reported financial and operational results for Q3, detailing continued progress across its AI-enabled DNA Damage Response programs. The company highlighted new scientific data, expanded collaborations, and increased visibility at major oncology conferences. More >

Water Treatment Firm Finds High-Performance Solution for $2.99B PFAS Market
Source: Streetwise Reports  (12/3/25)
Chemical Engineering magazine features BioLargo Inc. (OTCQX:BLGO) subsidiary BioLargo Equipment Solutions & Technologies Inc. (BEST) for its advancements in electrostatic PFAS treatment technology. Read why one expert likes this stock long-term. More >